BusinessActinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017By Nasdaq OMXAug 9, 2017, 11:30 AM UTC
BusinessActinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common StockBy Nasdaq OMXAug 2, 2017, 8:05 PM UTC
BusinessActinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase StockBy Nasdaq OMXJul 27, 2017, 8:06 PM UTC
BusinessActinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ETBy Nasdaq OMXJul 6, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming QuartersBy Nasdaq OMXJun 15, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing TeamsBy Nasdaq OMXJun 15, 2017, 11:00 AM UTC
BusinessActinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-BBy Nasdaq OMXJun 12, 2017, 11:00 AM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive OfficerBy Nasdaq OMXJun 9, 2017, 11:30 AM UTC
